Manufacturers of rare disease and specialty products in the U.S. face an increasingly intricate distribution landscape. What once looked like a relatively simple path from drug to patient now demands strategic alignment across state and federal compliance, logistics models, and evolving legislation that threatens to upend established networks.
The article we are spotlighting today opens the curtain to see several key emerging challenges for Pharma. A full read of the article will add significant color to this short summary Report.
State Licensure Regimes & Virtual Distribution Risks
Each U.S. state (and D.C.) enforces its own licensing rules for drug distributors, creating significant burdens for national operations. Many states now extend these requirements to “virtual distributors” that transfer title or broker products without physical facilities, meaning even remote or non-handling manufacturers may still need state licensure.
Distribution Models as Compliance Tools
To mitigate state licensing burdens, manufacturers are exploring variants of 3PL and title transfer models each carrying trade-offs in cost, control, regulatory risk, and operational complexity:
- A “flash title” model transfers ownership to a 3PL briefly to satisfy state licensing rules, though the 3PL may not perform storage or distribution.
- A full 3PL title model transfers both title and possession to the logistics provider, allowing the manufacturer to outsource licensure burdens to that party.
State-Level Network Restrictions & Limited Distribution Network Pressures
States are tightening oversight of “limited distribution networks” (LDNs) even prohibiting manufacturers from restricting distribution to out-of-state pharmacies without offering comparable local access or board-approved justification. Specialty drug makers relying on LDNs must monitor such laws and prepare for penalties.
Federal Healthcare Compliance Layers
Beyond state hurdles, any arrangement with 3PLs or distributors must respect Anti-Kickback rules and government price reporting obligations. Manufacturers must properly assess and document fair market value (FMV) for services rendered, especially when using novel title/3PL structures, to avoid kickback or overpayment risks.
For Pharma manufacturers in the rare/specialty segment, each drug’s distribution strategy must now be as carefully governed as its clinical strategy.
Rare Disease and Specialty Product Manufacturers: Distribution Model Considerations
CLICK HERE to read the full article
